<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00717990</url>
  </required_header>
  <id_info>
    <org_study_id>CT/05.35</org_study_id>
    <nct_id>NCT00717990</nct_id>
  </id_info>
  <brief_title>Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment</brief_title>
  <official_title>A Phase II Study of Irinotecan, Capecitabine and Avastin in Patients With Metastatic Colorectal Cancer, Who Have Progressed After 1ST Line Therapy With Folfox/Avastin.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of Crete</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital of Crete</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy of Irinotecan,Capecitabine and Avastin combination in&#xD;
      patients with no response to previous treatment with 5-Fluorouracil,Leucovorin,Eloxatin and&#xD;
      Avastin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this phase II study is to evaluate the efficacy of the combination XELIRI/AVASTIN&#xD;
      in patients with mCRC, who have progressed in first line treatment with FOLFOX/AVASTIN. For&#xD;
      AVASTIN was selected the dosing schedule of the trials TREE 1 and 2 [17], where Avastin was&#xD;
      combined with capecitabine and oxaliplatin in a three weeks schedule and with adaptation of&#xD;
      the dose in the 7,5 mg/kg&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor Accrual&#xD;
  </why_stopped>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>up to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time To Progression</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile</measure>
    <time_frame>Toxicity assessment on each chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Assessment every two cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms improvement</measure>
    <time_frame>Assessment every two cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XELIRI/Avastin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 2000 mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab 7.5 mg/kg intravenous (IV) on day 1 every 3 weeks for 6 cycles</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan 250 mg/m2 IV on day 1 every 3 weeks for 6 cycles</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Campto</other_name>
    <other_name>CPT-11</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed locally advanced or metastatic colorectal cancer&#xD;
&#xD;
          -  Measurable or evaluable disease according to the Response Evaluation Criteria in Solid&#xD;
             Tumors&#xD;
&#xD;
          -  ECOG performance status ≤ 2&#xD;
&#xD;
          -  Age 18 - 72 years&#xD;
&#xD;
          -  Patients who progress after 1st line therapy with FOLFOX/AVASTIN&#xD;
&#xD;
          -  Adequate liver (Bilirubin ≤ 1.5 upper normal limit, SGOT/SGPT ≤ 4 upper normal limit,&#xD;
             ALP ≤ 2.5 upper normal limit) renal (Creatinine ≤ 1.5 upper normal limit) and bone&#xD;
             marrow (ANC ≥ 1,500/mm3, PLT ≥100,000/mm3) function&#xD;
&#xD;
          -  Patients must be able to understand the nature of this study&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of serious cardiac disease (unstable angina, congestive heart&#xD;
             failure,uncontrolled cardiac arrhythmias)&#xD;
&#xD;
          -  History of myocardial infarction or stroke within 6 months&#xD;
&#xD;
          -  Clinically significant peripheral vascular disease&#xD;
&#xD;
          -  History of abdominal fistula, gastrointestinal perforation or intraabdominal abscess&#xD;
             within 28 days prior to Day 0&#xD;
&#xD;
          -  Major surgical procedure, open biopsy, or significant traumatic injury within 30 days&#xD;
             prior to Day 1&#xD;
&#xD;
          -  Presence of central nervous system or brain metastasis&#xD;
&#xD;
          -  Evidence of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  Blood pressure &gt; 150/100 mmHg&#xD;
&#xD;
          -  Pregnant or lactating woman&#xD;
&#xD;
          -  Life expectancy &lt; 3 months&#xD;
&#xD;
          -  Previous radiotherapy within the last 4 weeks or &gt; 25% of bone marrow&#xD;
&#xD;
          -  Metastatic infiltration of the liver &gt; 50%&#xD;
&#xD;
          -  Patients with chronic diarrhea (at least for 3 months) or partial bowel obstruction or&#xD;
             total colectomy&#xD;
&#xD;
          -  Active infection requiring antibiotics on Day 1&#xD;
&#xD;
          -  Second primary malignancy, except for non-melanoma skin cancer and in situ cervical&#xD;
             cancer&#xD;
&#xD;
          -  Psychiatric illness or social situation that would preclude study compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vassilis Georgoulias, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Crete, Dep of Medical Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Crete, Dep of Medical Oncology</name>
      <address>
        <city>Heraklion</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>July 16, 2008</study_first_submitted>
  <study_first_submitted_qc>July 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2008</study_first_posted>
  <last_update_submitted>October 6, 2015</last_update_submitted>
  <last_update_submitted_qc>October 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital of Crete</investigator_affiliation>
    <investigator_full_name>Vassilis Georgoulias, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Colorectal cancer</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>XELIRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

